Daily Roundup

Kingston Resources Strikes Gold with Jack's Hut Drilling Success

Kingston Resources is building momentum at its Mineral Hill project with excellent infill drilling results from the Jack's Hut deposit. The company is targeting Jack's Hut as its second underground ore source, and the latest results are reinforcing that ambition. The drilling confirmed the existing geological interpretation and bolstered confidence in the location, continuity, and grade of mineralisation around conceptual stope areas. Coming up in October, surface drilling will test potential depth extensions below the current resource. Kingston expects to roll out an updated Mineral Resource estimate for Jack's Hut in the March quarter of 2027.

Krakatoa Resources Uncovers High-Grade Gold and Antimony at Zopkhito

Over in Georgia, Krakatoa Resources is reporting impressive assay results from its 2026 drilling program at the Zopkhito Antimony-Gold Project. Multiple zones of significant mineralisation have emerged, with peak results hitting 17.1 grams per tonne of gold and 15.3 percent antimony. The highest-grade intercept came in at 1.8 metres grading 11.09g/t Au and 3.56% Sb. These results align nicely with 2025 data and historical high-grade finds, confirming the continuity of mineralisation across the project. Krakatoa is using the drilling program to convert a foreign resource estimate into a JORC 2012 standard Mineral Resource Estimate, with both surface and underground drilling continuing to expand the mineralised vein footprint.

Black Cat Syndicate Appoints Experienced Mining Executive

Black Cat Syndicate has appointed Chris Stone as Acting Managing Director, effective 8 September 2026. Stone brings over 35 years of mining industry experience across gold, nickel, copper, and coal operations. His appointment comes as the company searches for a permanent replacement, with Stone's leadership expected to guide the business through the transition while maintaining focus on safety, technical functions, and stakeholder engagement.

Echo IQ Faces FDA Setback on Heart Failure Device

Echo IQ received disappointing news from the FDA regarding its EchoSolv HF device. The initial 510(k) application received a Not Substantially Equivalent determination, meaning it won't clear for commercial use in its current form. The company is now reviewing the determination with regulatory and legal advisors and will engage with the FDA to explore available options. Despite the setback, Echo IQ remains confident in the clinical rationale for the technology and the unmet need it addresses. On the brighter side, the company maintains a strong financial position with over $105 million in cash, and uptake of its EchoSolv AS product in the US continues to grow. The broader R&D pipeline also remains robust.

BTC Health Grapples with Supply Chain Disruption

BTC Health has flagged a significant supply chain issue following the voluntary administration of Arna Pharma, the manufacturer of Bronchitol® and Aridol®. While BTC Health itself isn't financially exposed to Arna Pharma's troubles, the impact on product availability is real. BTC Pharma, BTC Health's distribution subsidiary, currently holds about eight months of Bronchitol® stock but less than a month of Aridol® inventory. The company is bracing for a sharp drop in sales—down to around $0.5 million in FY2027 without securing additional supply. BTC Pharma is actively engaging with Arna Pharma's administrators and relevant authorities to work out continuity arrangements. Arna Pharma has indicated its intention to recapitalize and maintain supply, though BTC Health can't independently verify that commitment.